Why the study?
It was unknown whether tirzepatide use is associated with a reduced risk of new-onset HF in patients with obesity.
Does tirzepatide reduce the risk of new-onset heart failure in adults with obesity?
Population
381,026 matched adults with obesity (BMI >30 kg/m²)
Comparison
Patients prescribed tirzepatide vs matched controls not receiving the drug
Design
Multi-center retrospective propensity score-matched cohort study
Follow-up
Within one year
Authors
Loading...
Hypothesis-generating for HF prevention in obesity; prospective RCTs needed before practice change.
Does tirzepatide reduce the risk of new-onset heart failure in adults with obesity?
In a large retrospective cohort, tirzepatide use in adults with obesity was associated with a nearly 50% reduction in the risk of new-onset heart failure and improved 1-year cardiovascular outcomes.
Wu et al. (2025) studied this question.